Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?

References

• Fredrick CM, Lin G, Johnson EA. Regulation of botulinum neurotoxin synthesis and toxin complex formation by arginine and glucose in clostridium botulinum ATCC 3502. Appl Environ Microbiol. 2017;83(13):e00642–17.
   PubMed Web of Science ®Google Scholar
• Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63(1):180–185.
   PubMed Web of Science ®Google Scholar
• Chagas TF, Almeida NV, Lisboa CO, et al. Duration of effectiveness of Botulinum toxin type A in excessive gingival display: a systematic review and meta-analysis. Braz Oral Res. 2018;32:e30.
   PubMed Web of Science ®Google Scholar
• Jadhao VA, Lokhande N, Habbu SG, et al. Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism. Indian J Dent Res. 2017;28(5):493–497.
   PubMedGoogle Scholar
• Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016;38(1):5.
   PubMedGoogle Scholar
• Khawaja SN, McCall W Jr, Dunford R, et al. Infield masticatory muscle activity in subjects with pain-related temporomandibular disorders diagnoses. Orthod Craniofac Res. 2015;1 18Suppl(1):137–145. DOI:10.1111/ocr.12077.
   Google Scholar
• White S, Ahmed B, Ondhia A. The effectiveness of Clostridium botulinum toxin A (Dysport®, AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study. Oral Surg. 2018;11(3):175–182. Doi:10.1111/ors.12338.
   Google Scholar
• Baker JS, Nolan PJ. Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: a case series. J Am Dent Assoc. 2017;148(1):33–39.
   PubMed Web of Science ®Google Scholar
• Al-Wayli H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J Clin Exp Dent. 2017 Jan 1;9(1):e112–e117. DOI:10.4317/jced.53084.
   PubMedGoogle Scholar
• Pihut M, Ferendiuk E, Szewczyk M, et al. The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. J Headache Pain. 2016;17:29.
   PubMed Web of Science ®Google Scholar
• Mor N, Tang C, Blitzer A. Temporomandibular myofacial pain treated with botulinum toxin injection. Toxins (Basel). 2015 Jul 24;7(8):2791–2800. DOI:10.3390/toxins7082791.
   PubMed Web of Science ®Google Scholar
• Lora VRMM, Clemente-Napimoga JT, Abdalla HB, et al. Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomandibular joint of rats. Toxicon. 2017;129:52–57.
   PubMed Web of Science ®Google Scholar
• Lora VRMM, Del Bel Cury AA, Jabbari B, et al. Botulinum toxin type A in dental medicine. J Dent Res. 2019 Dec;98(13):1450–1457. DOI:10.1177/0022034519875053.
   PubMed Web of Science ®Google Scholar
• Lacković Z. New analgesic: focus on botulinum toxin. Toxicon. 2020;179:1–7.
   PubMed Web of Science ®Google Scholar
• Lima MC, Rizzatti-Barbosa CM, and Caria PH. Application of botulinum toxin type A for pain reduction in trigeminal neuralgia: 6-month follow-up. Br J Dent. 2019;76:1495. DOI:10.18363/rbo.v76.2019.e1495
   Google Scholar
• Chaurand J, Pacheco-Ruíz L, Orozco-Saldívar H, et al. Efficacy of botulinum toxin therapy in treatment of myofascial pain. J Oral Sci. 2017;59(3):351–356.
   PubMed Web of Science ®Google Scholar
• Canales GDLT, Alvarez-Pinzon N, and Muñoz-Lora VRM, et al. Efficacy and safety of botulinum toxin type A on persistent myofascial pain: a randomized clinical trial. Toxins (Basel). 2020;12:395–408.
   PubMed Web of Science ®Google Scholar
• Bagis B, Ayaz EA, Turgut S, et al. Gender difference in prevalence of signs and symptoms of temporomandibular joint disorders: a retrospective study on 243 consecutive patients. Int J Med Sci. 2012;9(7):539–544.
   PubMed Web of Science ®Google Scholar
• Lora VRMM, Canales GDLT, and Gonçalves LM, et al. Prevalence of temporomandibular disorders in postmenopausal women and relationship with pain and HRT. Braz Oral Res. 2016;30:1e100–106. https://doi.org/10.1590/1807-3107BOR-2016.vol30.0100
   Web of Science ®Google Scholar
• Meloto CB, Segall SK, Smith S, et al. Locus do gene COMT: novas variantes funcionais. Pain. 2015;156(10):2072–2083.
   PubMedGoogle Scholar
• Meloto CB, Serrano PDO, Dasilva MCR, et al. Genomics and the new perspectives for temporomandibular disorders. Arch Oral Biol. 2011;56:1181–1191.
   PubMed Web of Science ®Google Scholar
• Lerman SF, Campbell CM, Buenaver LF, et al. Exploring the role of negative cognitions in the relationship between ethnicity, sleep and pain in women with temporomandibular joint disorder. J Pain. 2018;19(11):1342–1351.
   PubMed Web of Science ®Google Scholar
• Pimentel MJ, Gui M, Rizzatti-Barbosa CM. Relationship of temporomandibular disorders and sleep pattern changes in fibromyalgia syndrome - literature review. Full Dentistry Sci. 2016;8:114–122.
   Google Scholar
• Pimentel MJ, Gui MS, Aquino LMM, et al. Features of temporomandibular disorders in fibromyalgia syndrome. CRANIO®. 2013;31(1):40–45.
   Web of Science ®Google Scholar
• Gui MS, Pedroni CR, Aquino LMM, et al. Facial pain associated with fibromyalgia can be marked by abnormal neuromuscular control: a cross-sectional study. Phys Ther. 2013;93(8):1092–1101.
   PubMed Web of Science ®Google Scholar
• Plesh O, Adams SH, Gansky SA. Temporomandibular joint disorder and muscle disorders and comorbid pain in a US national sample. J Dor Orofac. 2011;25(3):190–198.
   Google Scholar
• Sampaio NM, Oliveira MC, Ortega AO, et al. Temporomandibular disorders in elderly individuals: the influence of institutionalization and sociodemographic factors. CODAS. 2017;29(2):e20160114.
   PubMed Web of Science ®Google Scholar
• Schiffman E, Ohrbach R, Truelove E, et al. Critérios de diagnóstico para desordens temporomandibulares (DC/TMD) para aplicações clínicas e de pesquisa: recomendações da Rede Internacional de Consórcios RDC/TMD e Grupo de Interesse Especial de Dor Orofacial. J Oral Facial Pain Headache. 2014;28(1):6–27.
   PubMed Web of Science ®Google Scholar
• Pereira JFJ, Goncalves DAG, Camparis CM, et al. Diagnostic criteria for temporomandibular disorders: clinical protocol and assessment instruments: Brazilian portuguese version. 25 May 2016; Pereira Jr. FJ, Gonçalves DAG. RIO DE JANEIRO: DC TMD, 2020. doi:10.11607/jop.1151
   Google Scholar
• Guarda-Nardini L, Manfredini D, Salamone M, et al. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. CRANIO®. 2008;26(2):126–135.
   Web of Science ®Google Scholar
• Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1–2):125–133. DOI:10.1016/j.pain.2003.10.008.
   PubMed Web of Science ®Google Scholar
• Matak I, Rossetto O, Lacković Z. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain. 2014;155(8):1516–1526.
   PubMed Web of Science ®Google Scholar
• Gui MS, Rizzatti-Barbosa CM. Chronicity factors of temporomandibular disorders: a critical review of the literature. Braz Oral Res. 2015;29:1–6.
   Web of Science ®Google Scholar
• De la Torre Canales G, Câmara-Souza MB, and do Amaral CF, et al. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017;21(3):727–734.
   PubMed Web of Science ®Google Scholar
• Tsai CY, Lin YC, Su B, et al. Masseter muscle fibre changes following reduction of masticatory function. Int J Oral Maxillofac Surg. 2012;41(3):394–399.
   PubMed Web of Science ®Google Scholar
• Balanta-Melo J, Toro-Ibacache V, Torres-Quintana MA, et al. Early molecular response and microanatomical changes in the masseter muscle and mandibular head after botulinum toxin intervention in adult mice. Ann Anat. 2018;216:112–119.
   PubMed Web of Science ®Google Scholar
• Raphael KG, Tadinada A, Bradshaw JM, et al. Osteopenic consequences of botulinum toxin injections in the masticatory muscles: a pilot study. J Oral Rehabil. 2014;41(8):555–563.
   PubMed Web of Science ®Google Scholar
• De la Torre Canales G, Manfredini D, Grillo CM, et al. Therapeutic effectiveness of a combined counseling plus stabilization appliance treatment for myofascial pain of the jaw muscles: a pilot study. CRANIO®. 2016;35(3):185–186.
   Google Scholar
• Martins APVB, Meloto CB, Rizzatti-Barbosa CMR. Counseling and oral splint for conservative treatment of temporomandibular dysfunction: preliminary study. Revista de Odontologia da UNESP (Online). 2016;1:1–3. DOI:10.1590/18072577.28515
   Google Scholar
• Grillo CM, Canales GDLT, Wada RS, et al. Psychological aspects of temporomandibular disorder patients: evaluations after acupuncture treatment. Revista Dor. 2015;16: 144–118. DOI:10.5935/1806-0013.20150022. 2015
   Google Scholar
• MLP P, Ed A, CMR B. Pharmacological guidelines for managing temporomandibular disorders. Braz J Oral Sci. 2004;3(10):503–505.
   Google Scholar
• Rizzatti-Barbosa CM, Martinelli DA, Ambrosano GMB, et al. Therapeutic response of Benzodiazepine, Orfenadrine Citrate and occlusal splint association in TMD pain. CRANIO®. 2003;21(2):116–120.
   Web of Science ®Google Scholar
• Safarpour Y, Jabbarin B. Botulinum toxin treatment of pain syndromes – an evidence based review. Toxicon. 2018;147:120–128.
   PubMed Web of Science ®Google Scholar